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We correlate regression of bone marrow ﬁbrosis (BMF) on day 30 and 100 after dose- reduced allogeneic
stem cell transplantation (allo-SCT) in 57 patients with primary or posteessential thrombocythemia/
polycythemia vera myeloﬁbrosis with graft function and survival. The distribution of International Prog-
nostic Scoring System (IPSS) risk score categories was 1 patient with low risk, 5 patients with
intermediate-1 risk, 18 patients with intermediate-2 risk, and 33 patients with high risk. Before allo-SCT,
41 patients (72%) were classiﬁed as XXX [mycloﬁbrosis (MF)]-3 and 16 (28%) were classiﬁed as MF-2 ac-
cording to the World Health Organization criteria. At postengraftment day þ30 (10 days), 21% of the
patients had near-complete or complete regression of BMF (MF-0/-1), and on day þ100 (20 days), 54%
were MF-0/-1. The 5-year overall survival rate at day þ100 was 96% in patients with MF-0/-1 and 57% for
those with MF-2/-3 (P ¼ .04). There was no difference in BMF regression at day þ100 between IPSS high-
risk and low/intermediate-risk patients. Complete donor cell chimerism at day þ100 was seen in 81% of
patients with MF-0/-1 and in 31% of those with MF-2/-3. Patients with MF-2/-3 at day þ100 were more
likely to be transfusion-dependent for either RBCs (P ¼ .014) or platelets (P ¼ .018). Rapid BMF regression
after reduced-intensity conditioning allo-SCT resulted in a favorable survival independent of IPSS risk score
at transplantation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bone marrow ﬁbrosis (BMF) is a hallmark of primary or
posteessential thrombocythemia (ET)/polycythemia vera
(PV) myeloﬁbrosis [1]. The ﬁbrogenesis is not completely
understood and probably caused by cytokines such as
platelet-derived growth factor, b ﬁbroblastederived
growth factor, or transforming growth factor b secreted
from clonal megakaryocytes and/or clonal monocyte/
histiocyte proliferation [2-4].
Fibrosis grade correlates with other clinical parameters,
including hemoglobin, myeloblasts, lactate dehydrogenase,
and spleen size [5]. Some studies have found a correlation
between grade of ﬁbrosis and survival [5-7]; however, others
did not report this correlation [8-11]. BMF is not included in
any of the currently used risk classiﬁcation schemes,
including Lille score, Cervantes score, International Prog-
nostic Scoring System (IPSS), Dynamic IPSS, and Dynamic
IPSS Plus [12-16]. BMF regression has been reported after
allogeneic stem cell transplantation (allo-SCT) [17] and, inedgments on page 815.
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14.02.019some cases, after treatment with IFN-a [18], pomalidomide
[19], and, more recently, ruxolitinib [20]; however, the
impact of ﬁbrosis resolutiondespecially the dynamics of
resolutiondon survival has not been studied to date.
Here we report the impact of dynamic of bone resolution
on survival and other graft-speciﬁc factors after dose-
reduced allo-SCT in a homogenously treated group of pa-
tients with advanced primary or post-ET/PV myeloﬁbrosis.PATIENTS AND METHODS
Between 2002 and 2010, a total of 109 patients underwent allo-SCT for
myeloﬁbrosis at the University Medical Center Hamburg-Eppendorf. For
inclusion, patients needed to have bone marrow histology investigated by a
reference pathologist (M.K., J.T., G.B., or H.K.) before reduced-intensity
conditioning allo-SCT and at least on day þ30 (2 weeks) and/or
day þ100 (1 month) postengraftment. Fifty-seven patients (median age,
57 years; range, 33-73 years) fulﬁlled the inclusion criteria. Bone marrow
histology was available at both days þ30 and þ100 in 35 patients, only at
day þ30 in 13 patients, and only at day þ100 in 9 patients. The risk proﬁle
was based on IPSS classiﬁcation [16].
One patient was classiﬁed as IPSS low risk; 5, as intermediate-1 risk; 17,
intermediate-2 risk, and 34, as high risk. The donor and recipient were
related in 11 cases and unrelated in 46 cases, and HLA-matched in 38 cases
and HLA-mismatched in 19 cases. The conditioning regimen comprised
busulfan 10 mg/kg orally or 10  0.8 mg/kg i.v. in combination with ﬂu-
darabine 150 mg/m2. Eleven patients received induction therapy with
amsacrine, ﬂudarabine, and cytarabine (FLAMSA), followed after a 3-day rest
by busulfan/ﬂudarabine. All patients received peripheral blood stem cell
grafts. Patient characteristics are summarized in Table 1.Transplantation.
Table 1
Patient Charcteristics (n ¼ 57)
Characteristic Value
Age, yr, median (range) 59 (9-76)
Males/females, n 32/25
Diagnosis, n
Primary myeloﬁbrosis 41
Post-ET/PV myeloﬁbrosis 16
Donor, n
Related 11
Unrelated 46
HLA-matched 38
HLA-mismatched 19
IPSS classiﬁcation at allo-SCT, n
Low 1
Intermediate-1 5
Intermediate-2 17
High 34
Blasts at allo-SCT, % median (range) 1 (0-17)
Recipient cytomegalovirus serostatus, n
Positive 38
Negative 19
Conditioning regimen, n
Busulfan 10 mg/kg/ﬂudarabine 150 mg/kg 46
FLAMSA þ busulfan 10 mg/kg/ﬂudarabine 150 mg/kg 11
Figure 1. Overall survival after reduced-intensity conditioning for myeloﬁ-
brosis (n ¼ 57).
Table 2
BMF at allo-SCT and at Day þ30 and Day þ100 after allo-SCT
Time BMF, n (%)
MF-0 MF-1 MF-2 MF-3
At allo-SCT (n ¼ 57) 0 0 16 (28) 41 (72)
Day þ30 (n ¼ 48) 3 (6) 7 (15) 17 (35) 21 (44)
Day þ100 (n ¼ 44) 11 (25) 13 (29) 12 (27) 8 (18)
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Organization classiﬁcation schemes [21]. For this study, only ﬁbrosis
regression was evaluated. In cases of residual osteosclerosis but no residual
ﬁbrosis, the patient was classiﬁed as (MF)-0.
All patients underwent bone marrow investigation before allo-SCT;
48 patients did so again at day þ30 and 44 at day þ100. Donor cell
chimerism and JAK2V617F mutation were assessed as decribed previously
[22]. Patient care was performed as reported elsewhere [23].
RESULTS
Engraftment and Graft-versus-Host Disease
Three graft failures were observed. All patients received a
second donation and successfully engrafted with leukocytes.
Themedian time to leukocyte engraftment (>1.0109 cells/L)
was 13 days (range, 9-26 days), and the median time to
platelet engraftment (>20109 cells/L)was 19 days (range, 9-
145 days). Acute graft-versus-host disease (GVHD) grade II-IV
occurred in 33% and severe grade III-IV GVHD in 14%. Chronic
GVHD was seen in 61% of the patients and classiﬁed as mild
(19%), moderate (33%), or severe (9%). Eleven patients (19%)
died during follow-up, either relapse-related (n ¼ 4) or
therapy-related (n ¼ 7).
Nonrelapse Mortality, Relapse, and Overall Survival
For the entire study population, nonrelapse mortality at
1 year was 11% (range, 3%-19%). The nonrelapse mortality
was calculated from day 0 onward; no patient died before
day þ30 after allo-SCT, and only 1 patient died between
day þ30 and day þ100. The cumulative incidence of
relapse at 3 years after allo-SCT was 20% (range, 4%-36%),
and the 5-year estimated overall survival was 79% (range,
65%-93%) (Figure 1). Causes of therapy-related death
included GVHD (n ¼ 2), cardiac failure (n ¼ 1), infectious
complications (n ¼ 1), organ toxicity (n ¼ 1), liver cirrhosis
(n ¼ 1), and secondary graft failure (n ¼ 1).
Dynamic of Fibrosis Regression and Survival
At the time of allo-SCT, 72% of the patients wereMF-3 and
28% were MF-2. At dayþ30 after allo-SCT, 6% were MF-0 and
15% were MF-1, and at day þ100, 25% were MF-0 and 29%
were MF-1 (Table 2).Survival of the patients with MF-0/-1 at day þ30 was
100%, in contrast to 71% (range, 51%-91%) for those with
MF-2/-3 (P ¼ .10). Patients with ﬁbrosis regression on
day þ100 to MF-0/-1 had an 5-year overall survival of 96%
(range, 88%-100%), compared with 57% (21%-93%) in those
with persistent MF-2/-3 (P ¼ .04) (Figure 1). The improved
survival of patients with MF-0/-1 at day þ100 posteallo-
SCT was related to a lower risk of treatment-related mor-
tality (15% versus 4%; P ¼ .20) and relapse at 1 year (20%
versus 0%; P ¼ .04) (Figure 2).
Regarding the ﬁbrosis reduction per level at day þ30, 28
(59%) had no reduction, 14 (29%) had a 1-grade reduction, 4
(8%) had a 2-grade reduction, and 2 (4%) had a 3-grade
reduction. At day þ100 posteallo-SCT, 9 patients (21%) had
no reduction in ﬁbrosis grade, whereas 16 patients (36%) had
a 1-grade reduction, 12 patients (27%) had a 2-grade reduc-
tion, and 7 patients (16%) had a 3-grade reduction (Table 3).
Five-year overall survival was improved for patients with a 2-
or 3-grade reduction at day þ100 in comparison to those
with persistent MF-2/-3 (95% [range, 85%-100%] versus 71%
[range, 47%-95%]); however, the difference did not reach
statistical signiﬁcance (P ¼ .19).Correlations between Fibrosis Regression and Donor Cell
Chimerism, Graft Function, Detection of JAK2V617F
Mutation, and IPSS
Comparing the results of ﬁbrosis resolution at day þ100
with other disease-speciﬁc factors revealed no correlation
Figure 2. Overall survival according to ﬁbrosis regression on day 30 (A) (based on 48 patient) and day 100 (B) (based on 44 patients) post allografting.
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mutation in peripheral blood. In 42% of the JAK2-positive
patients with MF-0/-1, JAK2V617F mutation was still
detectable in peripheral blood. In contrast, 81% of the pa-
tients with MF-0/-1 had complete donor cell chimerism,
compared with only 31% of those with MF-2/-3 (Table 4).
There was no signiﬁcant correlation between BMF resolu-
tion on day þ100 (MF-2/-3) and IPSS category at time of
allo-SCT, suggesting that disease status at transplantation
had no signiﬁcant impact on the dynamic of BMF
resolution.
At day þ100 posteallo-SCT, 53% of the patients were still
RBC transfusion-dependent, and 33% were platelet trans-
fusionedependent. Patients with MF-2/-3 at day þ100 were
more likely to be still RBC transfusionedependent (75%
versus 35%; P ¼ .014) and platelet transfusionedependent
(50% versus 13%; P ¼ .018). The median hemoglobin con-
centration, leukocyte count, and platelet count on day þ100
were higher in patients with MF-0/-1 compared with pa-
tients with MF-2/-3 (hemoglobin, 9.8 g/dL versus 8.7 g/dL
[P ¼ .40]; leukocytes, 3.9  109/L versus 3.6  109/L [P ¼ .90];Figure 3. Cumulative incidence of treatment-related mortality (A) andplatelets, 95  109/L versus 55  109/L [P ¼ .30]), suggesting
better (albeit not signiﬁcantly so) graft function in those
patients with rapid resolution of BMF by day þ100 (Table 4).
There was no difference in acute GVHD grade II-IV between
patients with and those without BMF resolution on dayþ100
(39% versus 30%; P¼ .70). Owing to the low number of events
within this study, multivariate analysis could not be
performed.
DISCUSSION
This study conﬁrms that complete resolution of BMF oc-
curs in patients with primary and post-ET/PV myeloﬁbrosis
after allo-SCT, as previously reported by us and others
[24,25]. Furthermore, this study shows for the ﬁrst time that
complete or near-complete resolution, deﬁned as MF-0/-1,
on day þ100 posteallo-SCT is associated with improved
survival. Interestingly, the speed of resolution at day þ30 or
day þ100 was not correlated with the IPSS classiﬁcation at
the time of allo-SCT, conﬁrming that reduced-intensity
conditioning can induce as rapid resolution of BMF as has
been reported for standard myeloablative conditioning [25].relapse (B) according to BMF regression at day þ100 (n ¼ 44).
Table 4
Correlations between Grade of Fibrosis at Dayþ100 and JAK2V617FMutation
(Only in JAK2-Positive Patients), Donor Cell Chimerism, Graft Function, Risk
Status (IPSS), Treatment-Related Mortality, and Overall Survival
Variable MF-0/-1 MF-2/-3 P
Value
JAK2V617F mutation, % .90
Negative 58 54
Positive 42 46
IPSS at treatment, % .50
Low/intermediate-1/-2 60 40
High 57 43
Transfusion dependency at day þ100, %
RBCs 35 75 .014
Platelets 13 50 .018
Complete donor cell chimerism, % 81 31 .03
Median hemoglobin at day þ100, g/dL 9.8 8.7 .40
Median leukocytes at day þ100,  109/L 3.9 3.6 .90
Median platelets at day þ100,  109/L 95 55 .30
Treatment-related mortality at 1 yr, % 4 15 .20
Relapse at 1 yr, % 0 20 .04
Five-yr overall survival, % 96 57 .04
Table 3
Reduction of BMF at Day þ30 and Day þ100 after allo-SCT
Time Level of Reduction, n (%)
None One
Grade
Two
Grades
Three
Grades
Day þ30 (n ¼ 48) 28 (59) 14 (29) 4 (8) 2 (4)
Day þ100 (n ¼ 44) 9 (21) 16 (36) 12 (27) 7 (16)
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resolution of BMF on day þ100 and disappearance of the
JAK2V617F mutant in peripheral blood detected by PCR.
Although there was a correlation between donor cell
chimerism and ﬁbrosis resolution on day þ100, the lack of
correlation with JAK2V617F mutant level might be explained
by the high sensitivity of the assay used in this study [22].
Furthermore, more rapid resolution of BMF was correlated
with improved graft function and signiﬁcantly fewer RBC
and platelet transfusions.
Retrospective studies have shown that grade of BMF
correlates with disease status [5], but the prognostic impact
remains controversial. Most of those previous studies did not
identify ﬁbrosis as independent risk factor, and thus none of
the currently used risk scores includes BMF. Even if the
number of included patients is too small to allow us to draw a
meaningful conclusion, this ﬁrst study on the dynamics of
ﬁbrosis regression and its impact on outcome suggests that a
more rapid resolution of BMF is associated with improved
graft function, less relapse, and improved long-termoutcomes
in patients with myeloﬁbrosis who undergo allo-SCT. How-
ever, this observation will not affect post-transplantation
patient management until methods that accelerate BMF
regression become available.
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